Skip to main content
Joanne Weidhaas, MD, Radiation Oncology, Los Angeles, CA

JoanneBWeidhaasMDPHD, MSM

Radiation Oncology Los Angeles, CA

Professor, David Geffen School of Medicine at UCLA

Dr. Weidhaas is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Weidhaas' full profile

Already have an account?

Education & Training

  • Stanford Graduate School of Business
    Stanford Graduate School of BusinessMS, Management, 2012 - 2013
  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterResidency, Radiation Oncology, 2000 - 2004
  • Caritas Carney HospitalInternship, Internal Medicine, 1999 - 2000
  • Tufts Sackler SchoolPhD, Molecular Biology and Microbiology, 1991 - 1999
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1999
  • Yale University
    Yale UniversityBS, Biology, 1986 - 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2015 - 2023
  • CT State Medical License
    CT State Medical License 2004 - 2017
  • NY State Medical License
    NY State Medical License 2000 - 2006
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Yale Cancer Center Award, “Most Influential Paper in the Field" 2009
  • Michael Fry Research Award 2009
  • Recognition of Clinical Excellence Award Yale School of Medicine, 2006
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab M...  
    Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S, Clin Cancer Res, 9/1/2014
  • A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma  
    Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastie..., Ann Oncol, 7/1/2014
  • Radiation therapy oncology group gynecologic oncology working group: comprehensive results  
    Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W Jr, Int J Gynecol Cancer, 6/1/2014
  • Join now to see all

Lectures

  • The KRAS-variant in Head and Neck Cancer as a Predictive Biomarker, results of RTOG 0522 
    6/1/2014
  • MicroRNAs in cancer risk, biology and treatment 
    4/1/2014
  • Yale Cancer Center Evening Oncology Series: Breast Cancer 
    Yale CME, New Haven, Connecticut - 1/17/2012
  • Join now to see all

Press Mentions

  • MiraKind.org Announces $50,000 Donation from George and Loretta Whitesides for COVID-19 Testing at Los Angeles-Area Skilled Nursing and Senior Care Facilities
    MiraKind.org Announces $50,000 Donation from George and Loretta Whitesides for COVID-19 Testing at Los Angeles-Area Skilled Nursing and Senior Care FacilitiesApril 14th, 2020
  • Much Shorter Radiation Treatment Found to Be Safe, Effective for People with Soft Tissue Sarcoma: Study Shows Radiation Therapy Can Be Cut from 5 Weeks to 5 Days
    Much Shorter Radiation Treatment Found to Be Safe, Effective for People with Soft Tissue Sarcoma: Study Shows Radiation Therapy Can Be Cut from 5 Weeks to 5 DaysFebruary 14th, 2020
  • MiraDx Enrolling First-Ever Non-Tumor Based microRNA Clinical Trial at UCLA
    MiraDx Enrolling First-Ever Non-Tumor Based microRNA Clinical Trial at UCLAJanuary 9th, 2020
  • Join now to see all

Grant Support

  • Let-7 Micrornas In Lung Cancer: Altering Growth And RadioresistanceNational Cancer Institute2009–2012
  • Defining The Genetic Basis Of The Radioresponse Using A C. Elegans Tissue ModelNational Cancer Institute2007–2011